Edition:
United States

Neuralstem Inc (CUR.OQ)

CUR.OQ on NASDAQ Stock Exchange Capital Market

1.17USD
20 Jul 2018
Change (% chg)

$-0.04 (-3.31%)
Prev Close
$1.21
Open
$1.22
Day's High
$1.23
Day's Low
$1.17
Volume
2,122
Avg. Vol
21,485
52-wk High
$6.04
52-wk Low
$0.89

Chart for

About

Neuralstem, Inc. (Neuralstem) is a clinical-stage biopharmaceutical company. The Company is engaged in research, development and commercialization of central nervous system therapies based on its human neuronal stem cells and its stem-cell derived small molecule compounds. The Company has approximately three assets: its NSI-189... (more)
No analyst recommendations are available for .

Overall

Beta: 1.46
Market Cap(Mil.): $18.19
Shares Outstanding(Mil.): 15.16
Dividend: --
Yield (%): --

Financials

  CUR.OQ Industry Sector
P/E (TTM): -- 28.87 33.05
EPS (TTM): -0.76 -- --
ROI: -85.55 13.59 13.17
ROE: -125.20 15.31 15.10

BRIEF-Neuralstem Q1 Loss Per Share $0.14

* NEURALSTEM PROVIDES BUSINESS UPDATE AND REPORTS FIRST QUARTER 2018 FISCAL RESULTS

May 15 2018

BRIEF-Neuralstem Announces First Surgery Completed In Cervical Cohort Of Phase 1 Clinical Trial In Patients With Chronic Spinal Cord Injury

* NEURALSTEM ANNOUNCES FIRST SURGERY COMPLETED IN CERVICAL COHORT OF PHASE 1 CLINICAL TRIAL IN PATIENTS WITH CHRONIC SPINAL CORD INJURY Source text for Eikon: Further company coverage:

Apr 10 2018

BRIEF-Neuralstem Says At Dec. 31, 2017, Cash And Investments Was $11.7 Mln Compared To $20.2 Mln At Dec. 31, 2016

* NEURALSTEM REPORTS YEAR END 2017 FISCAL RESULTS AND BUSINESS UPDATE

Apr 02 2018

Earnings vs. Estimates